Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy
Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy
复制标题
接受术前 SOX 方案化疗的胃癌患者的生存优势。
DOI：
10.1089/cbr.2020.3970
复制
发表时间：
2020-08-20
影响因子：
3.4
通讯作者：
Yang，Wenjun
中科院分区：
文献类型：
--
作者：
Zhang，Qian;Zhang，Qinghua;Yang，Wenjun
目的：探讨西北地区胃癌患者术前化疗（PECT）联合手术与手术联合术后化疗（POCT）是否能提高总生存率（OS）。材料与方法：作者纳入了2012年至2018年在宁夏医科大学总医院接受治疗的157例经组织学或胃镜病理检查确诊的胃癌患者。所有患者均于2019年1月在2周内通过电话随访。结果：38例患者接受PECT治疗，41例患者接受POCT治疗，40例患者接受单纯手术治疗，38例患者接受单纯化疗。进行了R 0切除术和随后的扩大淋巴结清扫术。化疗采用S-1、奥沙利铂、卡培他滨方案。接受PECT治疗的患者的OS长于接受POCT治疗的患者（风险比= 2.409，p = 0.037）。PECT组的5年OS率比POCT组高32.7%。结论：PECT与GC患者的OS更好相关，临床医生在GC治疗中应考虑PECT，但需要前瞻性研究进行确认。
Objective:This study addressed whether preoperative chemotherapy (PECT) plus surgery prolongs overall survival (OS) compared with surgery plus postoperative chemotherapy (POCT) among gastric cancer (GC) patients in Northwest China.Materials and Methods:The authors included 157 GC patients confirmed histologically or by gastroscopic pathological examination treated at the General Hospital of Ningxia Medical University of China between 2012 and 2018. All patients were followed up by telephone in January 2019 within a 2-week period. The endpoint was death due to GC or its complications.Results:Thirty-eight patients received PECT, 41 patients received POCT, 40 patients received surgery alone, and 38 patients received chemotherapy alone. Surgery was performed with R0 resection and subsequent extended lymph node dissection. Chemotherapy was performed with the S-1, oxaliplatin capecitabine regimen. Patients who received PECT had longer OS than those with POCT treatment (hazard ratio = 2.409,p= 0.037). The 5-year OS rate was 32.7% higher in the PECT group than in the POCT group.Conclusions:PECT was associated with better OS in GC patients and should be considered by clinicians in GC treatment, although prospective studies are needed for confirmation.